Introduction {#sec1}
============

Chiral polyheterocyclic structures, especially those containing potential pharmacophores with multiple stereocenters, have attracted the continuous attention of the synthetic community owing to their wide range of biological properties.^[@ref1]^ Despite extensive efforts, the development of novel synthetic strategies for the catalytic asymmetric synthesis of polyheterocyclic compounds from the readily available starting materials is still appealing but poses synthetic challenges, which may be attributed to the formation of multiple stereocenters in a completely stereocontrolled manner.

The enantioselective organocatalytic cascade reactions have been considered as powerful synthetic tools that enable the use of readily accessible starting materials to construct complex targets, particularly polyheterocyclic compounds with multiple stereocenters.^[@ref2]^ Electron-deficient 1-aza-1,3-butadienes are versatile synthetic building blocks that allow for a wide range of cascade reactions to prepare nitrogen-containing chiral polycyclic compounds.^[@ref3]^ Among the reported examples ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), 1-aza-1,3-butadienes are commonly used as a four-atom unit for \[4 + 2\] annulations, such as the inverse-electron-demand aza-Diels--Alder reaction, to construct hydropyridine derivatives,^[@ref4]^ whereas the applications of 1-aza-1,3-butadienes as a two-carbon unit for \[4 + 2\] annulations has been much less developed.^[@ref5]^

![Applications of 1-Aza-1,3-butadienes in \[4 + 2\] Annulation Reactions](ao-2018-02891p_0005){#sch1}

We recently found that chroman-2-ol could be directly used in the asymmetric enamine catalysis to access chiral polyheterocyclic compounds bearing a chromane fragment,^[@ref6]^ which is the main core of a wide variety of biologically active compounds.^[@ref7]^ Although 2-hydroxy cinnamaldehyde could serve as the valuable precursor of chroman-2-ol under iminium-catalyzed reduction conditions, this feature opens the possibility of discovering the new application of 2-hydroxy cinnamaldehyde for the preparation of structurally diverse polyheterocyclic molecules via sequential cascade procedures.^[@ref8]^ Indeed, there are other two reported examples of iminium-catalyzed enantioselective oxa-Michael-initiated cascade reactions, where the 2-hydroxy cinnamaldehyde was used to react with electron-deficient olefins,^[@ref9]^ such as nitroolefins and methyleneindolinones, for the preparation of polysubstituted chromane derivatives with good results. However, despite the wide applicability of 1-aza-1,3-butadienes in the sequential cascade synthesis of chiral polycyclic compounds, to the best of our knowledge, there is no report of asymmetric synthesis of highly functionalized chromane derivatives via \[4 + 2\] cycloaddition of 2-hydroxy cinnamaldehydes with 1-aza-1,3-butadienes as a two-carbon unit, leading to the products with the remaining ketimine moiety of 1-aza-1,3-butadienes, which offers ample opportunity for further transformations to provide diversified polyheterocyclic frameworks with high molecular and stereogenic complexity.

As a continuation of our ongoing investigation on the application of hemiacetals in organocatalytic asymmetric reactions to construct chiral polyheterocyclic structures,^[@ref10]^ we became interested in designing a novel and reliable organocatalytic strategy, which could impart precise assignment of the roles between the reaction components, for the direct assembly of skeletally diverse chromane-containing polyheterocyclic compounds. In this work, we envisioned that the reaction of 1-aza-1,3-butadienes **1** and 2-hydroxy cinnamaldehyde **2a** would proceed via two different reaction pathways, and the application of Hantzsch ester **4** is proposed to be the key to achieve role switch of both 2-hydroxy cinnamaldehydes and 1-aza-1,3-butadienes ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). In path a, the corresponding chroman-2-ol is formed first by the iminium-catalyzed in situ reduction of 2-hydroxy cinnamaldehyde **2a** in the presence of Hantzsch ester **4** as the organic hydride source,^[@ref11]^ which can subsequently undergo enamine-catalyzed \[4 + 2\] cycloaddition (or inverse-electron-demand aza-Diels--Alder reaction) to give hemiaminal intermediate **5** with the use of 1-aza-1,3-butadiene as a four-atom unit. The subsequent acid-catalyzed iminium ion formation of hemiaminal intermediate **5** provided the desired polycyclic aminal-containing product **6** by a ring-closure process, whereas in path b, 1-aza-1,3-butadiene would be used as a two-carbon unit and directly reacts with 2-hydroxy cinnamaldehyde via an iminium-catalyzed oxa-Michael/Michael sequence, leading to functionalized chromane derivative **7** bearing a ketimine moiety for further transformations. However, at least two challenging problems have to be addressed in the designed cascade process: (1) the depression of a background competitive reduction of 1-aza-1,3-butadienes in the presence of Hantzsch ester, due to the high reactivity of both alkene and ketimine moieties^[@ref12]^ and (2) the undesired formation of **7** in path a.

![Reaction Design: Two Different Organocatalytic Cascade Reaction Pathways](ao-2018-02891p_0006){#sch2}

Results and Discussion {#sec2}
======================

We initially focused our attention on the development of path a. As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, by using trimethylsilyl-protected prolinol catalyst **3a** and *p*-nitrobenzoic acid (*p*-NBA) as an additive in CHCl~3~ at 40 °C, we were delighted to find that the one-pot cascade reaction of 1-aza-1,3-butadiene **1a**, 2-hydroxy cinnamaldehyde **2a**, and Hantzsch ester **4** proceeded smoothly to afford the key hemiaminal intermediate **5** (confirmed by ^1^H NMR as the aminal form with 8:1 diastereoselectivity, whereas not the lactol form **5′**), followed by the *p*-toluenesulfonic acid (*p*-TsOH; 3.5 equiv *p*-TsOH was needed to diminish the effect of the generated stoichiometric byproduct Hantzsch pyridine on the reaction rate)-catalyzed intramolecular cyclization via iminium ion formation to furnish the desired polycyclic chromane product **6a** that contains three continuous stereogenic centers and an aminal moiety in good yield with excellent enantioselectivity as a single diastereoisomer (entry 1). It should be noted that the whole sequential cascade process was completed in a one-pot manner and only traces of competitive oxa-Michael initiated side product **7a** (\<5%) were detected, which indicated the high efficiency of this novel catalytic strategy. The use of other acidic additives resulted in slightly lower yields but with similar good enantioselectivities (entries 2--4). No reaction was observed with basic additive NaOAc (entry 5). After further examination of different solvents (entries 6--10), acetone was determined to be the most effective solvent with regard to the yield, enantioselectivity, and reaction times of both steps. The catalyst loading could be reduced to 10 mol % without compromising the efficiency and enantioselectivity (entry 11).

###### Optimization Studies for Path a[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-02891p_0002){#fx1}

                                                           *T* (h)               
  ------------------------------------ --------- --------- --------- ------ ---- ----
  1                                    *p*-NBA   CHCl~3~   24        2      65   98
  2                                    BA        CHCl~3~   24        2      59   94
  3                                    *o*-FBA   CHCl~3~   24        2      56   95
  4                                    AcOH      CHCl~3~   24        2      51   95
  5                                    NaOAc     CHCl~3~   \>48      2            
  6                                    *p*-NBA   toluene   30        2      48   99
  7                                    *p*-NBA   THF       27        \>12   61   91
  8                                    *p*-NBA   acetone   8         6      65   97
  9                                    *p*-NBA   MeCN      20        2      54   91
  10                                   *p*-NBA   MeOH      15        12     25   89
  11[d](#t1fn4){ref-type="table-fn"}   *p*-NBA   acetone   12        6      70   97

Unless otherwise noted, all reactions were carried out using **1a** (0.10 mmol, 1.0 equiv), **2a** (0.12 mmol, 1.2 equiv), **4** (0.12 mmol, 1.2 equiv) in solvent (0.2 mL) with **3a** (20 mol %) and additives (20 mol %) at 40 °C. After **1a** was consumed, *p*-TsOH (3.5 equiv) was added and then the reaction mixture was stirred at 25 °C for a specified time.

Isolated yield of **6a**.

Determined by high-performance liquid chromatography (HPLC) analysis on chiral stationary phases.

Reaction was carried out with **3a** (10 mol %) and *p*-NBA (20 mol %) in 0.1 mL acetone.

Having established the optimal reaction conditions for the application of 1-aza-1,3-butadiene **1a** as a four-atom unit in the reaction with 2-hydroxy cinnamaldehyde **2a** via a one-pot cascade process, the substrate scope for the preparation of polycyclic aminal-containing chromane derivatives **6** was then investigated with regard to **1** and **2**. As shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}, the reaction tolerates different substituted phenyl groups in the β-position of **1** (**6a**--**d**). Moreover, 2-naphtyl- and 2-thienyl-substituted **1** were effective substrates, affording **6e** and **6f** with excellent enantio- and diastereoselectivities. The functionalized **2b** and **2c** were also found to be applicable to this reaction sequence (**6g** and **6h**). In addition, the analogous 1-azadiene **1′** containing 1,2,3-benzoxathiazine-2,2-dioxide motif was effectively applied in the reaction with **2a** under the same reaction conditions, leading to **6h** in good yield and stereocontrol.

![Substrate Scope of Path a](ao-2018-02891p_0007){#sch3}

Inspired by the successful implementation of 1-aza-1,3-butadienes **1** as a four-atom unit to synthesize polycyclic aminal-containing chromane derivatives **6** by the reaction with 2-hydroxy cinnamaldehydes **2** in the presence of Hantzsch ester **4**, we further attempted to explore the use of 1-aza-1,3-butadienes **1** as a two-carbon unit in the reaction with 2-hydroxy cinnamaldehydes **2** in the absence of Hantzsch ester **4** to provide chromane-containing polycyclic products with more structural diversity. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, a screening of a model reaction between **1a** and **2a** was initiated in the absence of Hantzsch ester **4** to access the switched reaction pathway. However, to our surprise, under the optimized conditions for the synthesis of **6**, the oxa-Michael-initiated cascade reaction between **1a** and **2a** did not take place at all (entry 1). Interestingly, with benzoic acid (whose acidity is weaker than *p*-NBA) instead of *p*-NBA, the corresponding product **7a** was obtained in 40% yield with high enantioselectivity (entry 2). This suggests that basic additives may be beneficial to the reactivity. As expected, the basic additives, such as NaOAc and *N*,*N*-diisopropylethylamine (DIPEA), increased the rate of the cascade reaction (entries 3 and 4), which can be explained by a possible deprotonative activation of the 2-hydroxy cinnamaldehyde **2a** to form a more reactive intermediate with catalyst **3a**. Not surprisingly, the cascade reaction proceeded smoothly with only aminocatalyst **3a** and neither acidic nor basic additive was necessary (entry 5). On the other hand, after a brief screening of the solvent, the use of chlorinated solvent (1,2-dichloroethane, DCE) was found to be beneficial to the reaction rate (entry 6), whereas maintaining the enantioselectivity and all other solvents, such as MeCN, tetrahydrofuran (THF), and acetone, resulted in sluggish reactions (entries 7--9), leading to very poor conversions even after 96 h. Finally, catalyst screening revealed that *tert*-butyldimethylsilyl (TBS)-protected diphenylprolinol catalyst **3b** proved to be an effective catalyst without additives (entries 10 and 11), providing highly functionalized chromane product **7a** in 71% yield with excellent stereoselectivity (97% enantiomeric excess (ee), diastereomeric ratio \> 20:1). Therefore, with regard to enantioselectivity, the optimal conditions for the enantioselective preparation of **7a** were found to be the use of **3b** as a catalyst in DCE at 25 °C.

###### Optimization Studies for Path b[a](#t2fn1){ref-type="table-fn"}^,^[d](#t2fn4){ref-type="table-fn"}
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  entry   **3**    additive   solvent   *T* (h)   yield (%)[b](#t2fn2){ref-type="table-fn"}   ee (%)[c](#t2fn3){ref-type="table-fn"}
  ------- -------- ---------- --------- --------- ------------------------------------------- ----------------------------------------
  1       **3a**   *p*-NBA    CHCl~3~   \>96                                                   
  2       **3a**   BA         CHCl~3~   12        40                                          94
  3       **3a**   NaOAc      CHCl~3~   12        71                                          95
  4       **3a**   DIPEA      CHCl~3~   24        60                                          91
  5       **3a**              CHCl~3~   12        62                                          93
  6       **3a**              MeCN      \>96                                                   
  7       **3a**              THF       \>96                                                   
  8       **3a**              acetone   \>96                                                   
  9       **3a**              DCE       12        71                                          93
  10      **3b**              DCE       24        71                                          97
  11      **3c**              DCE       24        67                                          80

Unless otherwise specified, all reactions were carried out using **2a** (0.10 mmol, 1.0 equiv), **1a** (0.12 mmol, 1.2 equiv) in solvent (600 μL) with catalyst **3** (20 mol %) and additives (20 mol %) at 25 °C for a specified time.

Isolated yield of **7a**.

Determined by chiral HPLC analysis on the products after the in situ Wittig reaction with Ph~3~P=CHCOPh; see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02891/suppl_file/ao8b02891_si_003.pdf) for more details.

TBS = *tert*-butyldimethylsilyl; TES = triethylsilyl.

Subsequently, the substrate scope for the one-pot cascade sequence was explored. As shown in [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}, highly stereoselective reactions proceeded using an array of 1-aza-1,3-butadienes **1** with electron-withdrawing or electron-donating substituents on the aromatic ring at different positions (**7a**--**d**). Excellent enantioselectivities were also gained for 2-naphtyl-substituted **1** (**7e**). 2-Hydroxy cinnamaldehyde **2b** bearing a fluoro substituent on the aryl ring provided the desired product **7f** in a good yield and with excellent stereoselectivity. Additionally, the analogous 1-azadiene **1′** containing the 1,2,3-benzoxathiazine-2,2-dioxide motif was effectively applied in the cascade reaction process, leading to **7g** in good yield and stereocontrol.

![Substrate Scope of Path b](ao-2018-02891p_0008){#sch4}

To explore the utility of this synthetic method, a larger-scale synthesis of product **7a** was performed under the standard conditions ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). To our delight, this larger-scale reaction (0.5 mmol) proceeded smoothly to provide chromane product **7a** containing an aldehyde group and a ketimine moiety. As mentioned above, the remaining ketimine moiety in the structure of **7a** could be potentially used for further transformations. The in situ Wittig reaction of **7a** and ylide **8** generated enone **9**, followed by the formation of an aminal fragment by the nucleophilic attack of MeOH to the ketimine moiety, which facilitated a subsequent intramolecular aza-Michael addition to give polyheterocyclic product **10** in good isolated yield (40% over three steps) and with high structural and stereogenic complexity. It should be noted that product **10** was obtained as a single diastereoisomer bearing five stereocenters and one is a tetrasubstituted stereogenic center.

![Larger-Scale Synthesis and Useful Transformations](ao-2018-02891p_0001){#sch5}

The absolute configuration of product **6a** (CCDC 1873976) and **10** (CCDC 1873974) was unequivocally determined by X-ray crystallographic analysis (see [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"} for **6a** and [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"} for **10**; the H atoms are omitted for clarity) and all other products were assigned by analogy.

Conclusions {#sec3}
===========

In summary, we have developed two asymmetric organocatalytic competitive cascade reaction pathways: (1) 1-aza-1,3-butadienes were used as a four-atom unit to react with 2-hydroxy cinnamaldehydes via a one-pot \[4 + 2\] cycloaddition/iminium ion induced aminal formation cascade sequence and (2) 1-aza-1,3-butadienes were used as a two-carbon unit to react with 2-hydroxy cinnamaldehydes via an oxa-Michael/Michael cascade sequence. The application of Hantzsch ester is proposed to be the key to achieve the switch between these two different cascade reaction pathways, providing polycyclic chromane-containing compounds with high structural and stereogenic complexity. Finally, the designed cascade sequence is amenable to a larger scale, with a negligible difference in yield and stereoselectivity. Further functionalization on the ketimine moiety of the products led to a more complex and diverse polyheterocyclic compound.

General Methods {#sec3.1}
---------------

^1^H and ^13^C NMR spectra were recorded by an Agilent DD2-500 MHz NMR spectrometer, and the chemical shifts (δ) for ^1^H and ^13^C are given in parts per million (ppm) relative to residual signals of the solvent (CDCl~3~ at 7.26 ppm ^1^H NMR and 77.16 ppm ^13^C NMR). The chemical shifts (δ) for some residual solvents in CDCl~3~ are labeled in the spectra (H~2~O at 1.56 ppm ^1^H NMR, CH~2~Cl~2~ at 5.30 ppm ^1^H NMR, ethyl acetate at 4.12, 2.05, 1.06 ppm ^1^H NMR, and diethyl ether at 3.48, 1.21 ppm ^1^H NMR, grease 1.26, 0.86 ppm ^1^H NMR). Coupling constants are given in hertz. The following abbreviations are used to indicate the multiplicity: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; and m, multiplet. High-resolution mass spectra (HRMS) are obtained with the Waters Q-Tof Ultima Global. X-ray data are analyzed from the Zhongke Chemical Technology Service Center. Optical rotations are reported as follows: \[α\]~D~^20^ (*c* in g per 100 mL, solvent). All reactions are carried out at the bench with commercial reagents and solvent without further purification. Chiral HPLC analysis is performed on a HITACHI Chromaster. Daicel Chiralpak IA, IB, and IC columns with *i*-PrOH/*n*-hexane/CH~2~Cl~2~ as the eluent are used. HPLC traces were compared to racemic samples prepared by a mixture of two enantiomeric final products obtained using (*S*) and (*R*) catalysts.

Materials {#sec3.2}
---------

Commercial reagents and solvents from Sigma-Aldrich, Fluka, Adamas, Aladdin, J&K, Meryer, Energy, and Alfa Aesar are used as-received without further purification. The catalysts (*S*)- and (*R*)-diphenylprolinol silyl ether are commercially available from Daicel Chiral Technologies. All of the 2-hydroxy cinnamaldehydes **2** are synthesized from the corresponding salicylaldehydes via the Wittig reaction.^[@ref9]^ The substituted cyclic 1-azadienes **1** were prepared from 3-methylbenzo\[*d*\]isothiazole 1,1-dioxide and the corresponding aldehyde.^[@ref4]^

General Procedure for the Asymmetric Synthesis of Polycyclic Chromane-Containing Products **6** {#sec3.3}
-----------------------------------------------------------------------------------------------

A glass vial equipped with a magnetic stirring bar was charged with **2** (0.12 mmol, 1.2 equiv), **3a** (3.2 mg, 0.01 mmol), and *p*-NO~2~C~6~H~4~COOH (3.4 mg, 0.02 mmol) in acetone (0.1 mL) at 40 °C, and then Hantzsch ester **4** (30 mg, 0.12 mmol) and **1** (0.10 mmol, 1.0 equiv) were added simultaneously. Reactions were carried out at 40 °C. After **1** was consumed, *p*-TsOH (60 mg, 0.35 mmol) and additional acetone (0.1 mL) were added, and the reaction mixture was then stirred at 25 °C for another 6 h. After the reaction was completed, the product was purified by column chromatography on silica gel using petroleum ether--ethyl acetate solvent mixture as the eluent to provide the desired polycyclic chromane-containing products **6**.

### (6*S*,6*aR*,12*aR*)-6-Phenyl-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6a**) {#sec3.3.1}

White solid (32 mg, 79%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.88 (d, *J* = 7.8 Hz, 1H), 7.68--7.63 (m, 2H), 7.60 (t, *J* = 7.3 Hz, 1H), 7.38--7.30 (m, 3H), 7.19--7.16 (m, 3H), 7.02 (d, *J* = 7.3 Hz, 1H), 6.99--6.89 (m, 2H), 6.04 (d, *J* = 2.0 Hz, 1H), 5.74 (d, *J* = 2.5 Hz, 1H), 3.60 (dd, *J* = 10.3, 2.3 Hz, 1H), 3.06 (dd, *J* = 17.0, 5.8 Hz, 1H), 2.67 (dd, *J* = 17.0, 2.3 Hz, 1H), 2.56--2.41 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.6, 142.0, 133.2, 132.4, 130.2, 129.4, 128.9, 128.5, 128.5, 128.0, 127.4, 121.7, 121.4, 121.3, 118.6, 117.4, 104.2, 76.6, 39.4, 37.4, 27.6. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~20~NO~3~S^+^*m*/*z*: 402.1158; found: 402.1162. \[α\]~D~^20^ −103.5 (*c* = 0.50 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis on Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 80:20, 1 mL/min), λ = 227 nm, *t*~major~ = 15.27 min, *t*~minor~ = 24.89 min, ee = 98%.

### (6*S*,6*aR*,12*aR*)-6-(*p*-Tolyl)-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6b**) {#sec3.3.2}

White solid (18 mg, 44%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.87 (d, *J* = 7.7 Hz, 1H), 7.72--7.53 (m, 3H), 7.17 (d, *J* = 7.1 Hz, 3H), 7.06--7.01 (m, 3H), 6.95--6.91 (m, 2H), 6.03 (s, 1H), 5.71 (s, 1H), 3.55 (d, *J* = 10.1 Hz, 1H), 3.05 (dd, *J* = 16.9, 5.5 Hz, 1H), 2.67 (d, *J* = 17.0 Hz, 1H), 2.45 (brs, 1H), 2.37 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.6, 138.9, 137.1, 133.1, 132.4, 130.2, 129.6, 129.3, 129.0, 128.4, 128.3, 128.0, 121.7, 121.3, 121.2, 118.6, 117.4, 104.5, 76.6, 38.9, 37.4, 27.6, 21.1. ESI-HRMS: \[M + H\]^+^ calcd. For C~25~H~22~NO~3~S^+^*m*/*z*: 416.1315; found: 416.1310. \[α\]~D~^20^ −104.4 (*c* = 0.58 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis on Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 80:20, 1 mL/min), λ = 225 nm, *t*~major~ = 12.60 min, *t*~minor~ = 19.83 min, ee = 99%.

### (6*S*,6*aR*,12*aR*)-6-(4-Chlorophenyl)-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6c**) {#sec3.3.3}

White solid (24 mg, 56%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.88 (d, *J* = 7.8 Hz, 1H), 7.69--7.64 (m, 2H), 7.64--7.57 (m, 1H), 7.33 (d, *J* = 8.3 Hz, 2H), 7.17 (t, *J* = 7.7 Hz, 1H), 7.10 (d, *J* = 8.3 Hz, 2H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.98--6.90 (m, 2H), 6.03 (d, *J* = 2.1 Hz, 1H), 5.67 (d, *J* = 2.6 Hz, 1H), 3.58 (dd, *J* = 10.5, 2.5 Hz, 1H), 3.07 (dd, *J* = 17.0, 5.9 Hz, 1H), 2.62 (dd, *J* = 17.1, 2.4 Hz, 1H), 2.48--2.37 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.5, 140.5, 133.3, 133.2, 132.4, 130.4, 129.8, 129.3, 129.1, 128.8, 128.8, 128.2, 121.8, 121.4, 121.3, 118.3, 117.5, 103.4, 76.4, 38.7, 37.4, 27.6. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~19~ClNO~3~S^+^*m*/*z*: 436.0769; found: 436.0764. \[α\]~D~^20^ −123.4 (*c* = 0.67 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis on Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 75:25, 1 mL/min), λ = 225 nm, *t*~major~ = 11.91 min, *t*~minor~ = 24.59 min, ee = 99%.

### (6*S*,6*aR*,12*aR*)-6-(*m*-Tolyl)-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6d**) {#sec3.3.4}

White solid (21 mg, 51%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.87 (d, *J* = 7.5 Hz, 1H), 7.72--7.53 (m, 3H), 7.25--7.11 (m, 3H), 7.07--6.86 (m, 5H), 6.03 (s, 1H), 5.72 (s, 1H), 3.55 (d, *J* = 9.9 Hz, 1H), 3.05 (dd, *J* = 16.8, 5.2 Hz, 1H), 2.67 (d, *J* = 16.9 Hz, 1H), 2.47 (brs, 1H), 2.35 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.6, 141.9, 138.7, 133.2, 132.4, 130.2, 129.4, 129.1, 129.0, 128.8, 128.4, 128.2, 128.0, 125.6, 121.7, 121.4, 121.3, 118.6, 117.4, 104.4, 76.6, 39.3, 37.3, 27.7, 21.4. ESI-HRMS: \[M + H\]^+^ calcd. For C~25~H~22~NO~3~S^+^*m*/*z*: 416.1315; found: 416.1317. \[α\]~D~^20^ −138.5 (*c* = 1.25 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 75 :25, 1 mL/min), λ = 225 nm, *t*~major~ = 9.23 min, *t*~minor~ = 12.97 min, ee = 95%.

### (6*S*,6*aR*,12*aR*)-6-(Naphthalen-2-yl)-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6e**) {#sec3.3.5}

White solid (21 mg, 47%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.89 (d, *J* = 7.8 Hz, 1H), 7.88--7.83 (m, 2H), 7.83--7.76 (m, 1H), 7.70--7.64 (m, 2H), 7.63--7.57 (m, 2H), 7.55--7.46 (m, 2H), 7.30 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.20 (t, *J* = 7.7 Hz, 1H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.99--6.94 (m, 2H), 6.08 (d, *J* = 2.1 Hz, 1H), 5.80 (d, *J* = 2.6 Hz, 1H), 3.77 (dd, *J* = 10.5, 2.4 Hz, 1H), 3.07 (dd, *J* = 17.0, 5.9 Hz, 1H), 2.69 (dd, *J* = 17.1, 2.3 Hz, 1H), 2.62--2.58 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.7, 139.3, 133.4, 133.2, 132.7, 132.4, 130.3, 129.4, 128.9, 128.8, 128.6, 128.1, 127.7, 127.7, 127.5, 126.5, 126.1, 126.1, 121.8, 121.4, 121.3, 118.6, 117.5, 104.2, 76.6, 39.5, 37.3, 27.7. ESI-HRMS: \[M + H\]^+^ calcd. For C~28~H~22~NO~3~S^+^*m*/*z*: 452.1315; found: 452.1311. \[α\]~D~^20^ −67.7 (*c* = 0.83 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 70:30, 1 mL/min), λ = 225 nm, *t*~major~ = 13.50 min, *t*~minor~ = 22.85 min, ee = 97%.

### (6*S*,6*aR*,12*aR*)-6-(Thiophen-2-yl)-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6f**) {#sec3.3.6}

White solid (18 mg, 44%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.86 (d, *J* = 7.8 Hz, 1H), 7.69--7.64 (m, 2H), 7.63--7.56 (m, 1H), 7.26 (d, *J* = 3.7 Hz, 1H), 7.17 (t, *J* = 7.7 Hz, 1H), 7.04 (d, *J* = 7.5 Hz, 1H), 6.99 (dd, *J* = 5.1, 3.5 Hz, 1H), 6.96--6.92 (m, 2H), 6.87 (d, *J* = 3.4 Hz, 1H), 6.03 (d, *J* = 2.2 Hz, 1H), 5.76 (d, *J* = 2.8 Hz, 1H), 3.95 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.12 (dd, *J* = 17.0, 5.9 Hz, 1H), 2.80 (dd, *J* = 17.1, 3.3 Hz, 1H), 2.56--2.52 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.5, 145.2, 133.2, 132.6, 130.4, 129.4, 128.8, 128.3, 128.1, 127.0, 125.9, 124.8, 121.8, 121.4, 121.4, 118.5, 117.5, 103.4, 76.5, 37.9, 35.2, 27.6. ESI-HRMS: \[M + H\]^+^ calcd. For C~22~H~18~NO~3~S~2~^+^*m*/*z*: 408.0723; found: 408.0727. \[α\]~D~^20^ −131.4 (*c* = 1.17 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 75:25, 1 mL/min), λ = 225 nm, *t*~major~ = 13.22 min, *t*~minor~ = 22.00 min, ee = 95%.

### (6*S*,6*aR*,12*aR*)-9-Fluoro-6-phenyl-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6g**) {#sec3.3.7}

White solid (29 mg, 70%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.87 (d, *J* = 7.8 Hz, 1H), 7.69--7.64 (m, 2H), 7.60 (t, *J* = 7.2 Hz, 1H), 7.39--7.31 (m, 3H), 7.17 (d, *J* = 7.2 Hz, 2H), 6.91--6.86 (m, 2H), 6.74 (d, *J* = 8.2 Hz, 1H), 6.00 (s, 1H), 5.73 (d, *J* = 2.1 Hz, 1H), 3.57 (d, *J* = 10.0 Hz, 1H), 3.04 (dd, *J* = 17.2, 5.8 Hz, 1H), 2.65 (d, *J* = 17.2 Hz, 1H), 2.53--2.42 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 158.5, 156.6, 147.5, 141.8, 133.3, 132.4, 130.3, 129.0, 128.8, 128.6, 128.4, 127.6, 121.4, 121.3, 119.9, 119.9, 118.6, 118.5, 115.3, 115.1, 115.0, 114.8, 104.0, 76.6, 39.6, 37.1, 27.7. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~19~FNO~3~S^+^*m*/*z*: 420.1064; found: 420.1066. \[α\]~D~^20^ −129.0 (*c* = 1.92 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 75 :25, 1 mL/min), λ = 225 nm, *t*~major~ = 11.73 min, *t*~minor~ = 19.69 min, ee = 94%.

### (6*S*,6*aR*,12*aR*)-9-Methyl-6-phenyl-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,2-*e*\]pyridine 14,14-Dioxide (**6h**) {#sec3.3.8}

White solid (31 mg, 75%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.87 (d, *J* = 7.8 Hz, 1H), 7.68--7.62 (m, 2H), 7.61--7.57 (m, 1H), 7.38--7.30 (m, 3H), 7.17 (d, *J* = 7.0 Hz, 2H), 6.97 (d, *J* = 8.2 Hz, 1H), 6.88--6.79 (m, 2H), 6.00 (d, *J* = 2.1 Hz, 1H), 5.73 (d, *J* = 2.6 Hz, 1H), 3.60 (dd, *J* = 10.3, 2.4 Hz, 1H), 3.02 (dd, *J* = 17.0, 5.9 Hz, 1H), 2.62 (dd, *J* = 17.1, 2.4 Hz, 1H), 2.49--2.41 (m, 1H), 2.27 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 149.3, 142.1, 133.1, 132.4, 130.9, 130.2, 129.6, 129.0, 128.9, 128.7, 128.6, 128.5, 127.4, 121.3, 121.3, 118.2, 117.2, 104.2, 76.5, 39.4, 37.5, 27.6, 20.6. ESI-HRMS: \[M + H\]^+^ calcd. For C~25~H~22~NO~3~S^+^*m*/*z*: 416.1315; found: 416.1309. \[α\]~D~^20^ −167.7 (*c* = 1.17 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IA column (*n*-hexane/*i*-PrOH = 75:25, 1 mL/min), λ = 210 nm, *t*~major~ = 11.40 min, *t*~minor~ = 26.86 min, ee = 99%.

### (6*S*,6*aR*,12*aR*)-6-Phenyl-6*a*,12*a*-dihydro-6*H*,7*H*-benzo\[*e*\]chromeno\[3′,2′:5,6\]pyrido\[1,2-*c*\]\[1,2,3\]oxathiazine 14,14-Dioxide (**6i**) {#sec3.3.9}

The reaction was conducted following the general procedure; after **1i** was consumed, the intermediate was purified by flash column chromatography and then dissolved in CH~2~Cl~2~ (1.0 mL). BF~3~·Et~2~O (3.0 equiv) was added at 0 °C, the reaction mixture was stirred at 25 °C for 1 h, and the product was purified by column chromatography. White solid (25 mg, 60%); ^1^H NMR (500 MHz, CDCl~3~) δ 7.60 (d, *J* = 7.3 Hz, 1H), 7.42--7.29 (m, 4H), 7.26--7.22 (m, 1H), 7.21--7.16 (m, 4H), 7.04 (d, *J* = 7.5 Hz, 1H), 6.99--6.89 (m, 2H), 6.11 (d, *J* = 1.9 Hz, 1H), 5.80 (d, *J* = 2.4 Hz, 1H), 3.53 (dd, *J* = 11.7, 2.2 Hz, 1H), 3.06 (dd, *J* = 17.1, 5.8 Hz, 1H), 2.62 (d, *J* = 17.1 Hz, 1H), 2.49 (dd, *J* = 11.7, 5.9 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 151.6, 148.4, 141.7, 130.5, 129.5, 129.3, 128.9, 128.5, 128.1, 127.5, 126.4, 124.6, 121.9, 119.5, 119.4, 118.3, 117.4, 109.5, 80.3, 38.5, 36.2, 27.7. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~20~NO~4~S^+^*m*/*z*: 418.1108; found: 418.1111. \[α\]~D~^20^ −133.9 (*c* = 1.08 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 75:22:3, 1 mL/min), λ = 270 nm, *t*~major~ = 6.13 min, *t*~minor~ = 5.10 min, ee = 92%.

General Procedure for Asymmetric Synthesis of Trisubstituted Chromane Products **7** {#sec3.4}
------------------------------------------------------------------------------------

A glass vial equipped with a magnetic stirring bar was charged with **2** (0.10 mmol, 1.0 equiv), **3b** (7.2 mg, 0.02 mmol) in CHCl~3~ (0.6 mL) at 25 °C, and then **1** (0.12 mmol, 1.2 equiv) was added. After specified time, the product was purified by column chromatography on silica gel using the petroleum ether--ethyl acetate solvent mixture as the eluent to provide the desired trisubstituted chromane product **7**.

### 2-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-2-phenylchroman-4-yl)acetaldehyde (**7a**) {#sec3.4.1}

Pale yellow solid (30 mg, 71%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.69 (s, 1H), 7.73 (d, *J* = 7.5 Hz, 1H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.39 (dd, *J* = 11.1, 4.1 Hz, 1H), 7.36 (d, *J* = 7.3 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 1H), 7.24 (d, *J* = 7.8 Hz, 1H), 7.16--7.10 (m, 3H), 7.07--7.02 (m, 3H), 5.15 (d, *J* = 9.4 Hz, 1H), 4.36--4.24 (m, 1H), 3.88 (dd, *J* = 10.7, 9.6 Hz, 1H), 3.16 (ddd, *J* = 17.2, 5.7, 1.3 Hz, 1H), 2.72 (ddd, *J* = 17.3, 4.2, 1.9 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.9, 176.8, 154.4, 139.1, 137.5, 133.4, 133.3, 130.8, 128.8, 128.6, 128.4, 126.8, 126.6, 124.0, 122.5, 122.2, 122.0, 117.7, 81.3, 46.6, 45.6, 36.0. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~20~NO~4~S^+^*m*/*z*: 418.1108; found: 418.1105. \[α\]~D~^20^ +18.8 (*c* = 1.25 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 16.46 min, *t*~minor~ = 10.45 min, ee = 97%.

### 2-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-2-(*p*-tolyl)chroman-4-yl)acetaldehyde (**7b**) {#sec3.4.2}

Pale yellow solid (28 mg, 65%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.69 (t, *J* = 1.4 Hz, 1H), 7.74 (d, *J* = 7.5 Hz, 1H), 7.56 (td, *J* = 7.5, 0.7 Hz, 1H), 7.41 (td, *J* = 7.6, 0.9 Hz, 1H), 7.30 (d, *J* = 8.0 Hz, 1H), 7.25--7.20 (m, 3H), 7.16 (d, *J* = 7.8 Hz, 1H), 7.06--7.00 (m, 2H), 6.94 (d, *J* = 7.8 Hz, 2H), 5.12 (d, *J* = 9.4 Hz, 1H), 4.30--4.24 (m, 1H), 3.87 (dd, *J* = 10.8, 9.5 Hz, 1H), 3.15 (ddd, *J* = 17.2, 5.7, 1.4 Hz, 1H), 2.70 (ddd, *J* = 17.3, 4.2, 2.0 Hz, 1H), 2.12 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.9, 176.9, 154.5, 139.1, 138.7, 134.4, 133.3, 133.3, 130.8, 129.2, 128.3, 126.7, 126.5, 124.2, 122.5, 122.3, 121.9, 117.7, 81.2, 46.6, 45.6, 36.1, 20.9. ESI-HRMS: \[M + H\]^+^ calcd. For C~25~H~22~NO~4~S^+^*m*/*z*: 432.1264; found: 432.1268. \[α\]~D~^20^ +12.8 (*c* = 1.17 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 18.41 min, *t*~minor~ = 9.74 min, ee = 97%.

### 2-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-2-(*m*-tolyl)chroman-4-yl)acetaldehyde (**7c**) {#sec3.4.3}

Pale yellow solid (29 mg, 67%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.69 (s, 1H), 7.74 (d, *J* = 7.5 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.32 (d, *J* = 7.8 Hz, 1H), 7.27--7.22 (m, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.11 (d, *J* = 7.2 Hz, 2H), 7.06--7.01 (m, 3H), 6.82 (d, *J* = 7.5 Hz, 1H), 5.10 (d, *J* = 9.3 Hz, 1H), 4.37--4.23 (m, 1H), 3.85 (dd, *J* = 10.7, 9.6 Hz, 1H), 3.26--3.08 (m, 1H), 2.72 (ddd, *J* = 17.2, 4.1, 1.9 Hz, 1H), 2.14 (s, 3H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.9, 176.8, 154.5, 139.1, 138.4, 137.3, 133.3, 133.2, 130.9, 129.4, 128.6, 128.3, 127.3, 126.8, 123.9, 123.3, 122.5, 122.1, 121.9, 117.7, 81.4, 46.6, 45.6, 35.9, 21.0. ESI-HRMS: \[M + H\]^+^ calcd. For C~25~H~22~NO~4~S^+^*m*/*z*: 432.1264; found: 432.1266. \[α\]~D~^20^ +22.5 (*c* = 1.17 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 13.91 min, *t*~minor~ = 9.34 min, ee = 98%.

### 2-((2*R*,3*S*,4*R*)-2-(4-Chlorophenyl)-3-(1,1-dioxidobenzo\[*d*\]isothiazol-3-yl)chroman-4-yl)acetaldehyde (**7d**) {#sec3.4.4}

Yellow solid (32 mg, 70%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.68 (s, 1H), 7.78 (d, *J* = 7.5 Hz, 1H), 7.61 (td, *J* = 7.6, 0.7 Hz, 1H), 7.47 (td, *J* = 7.7, 0.9 Hz, 1H), 7.32--7.29 (m, 3H), 7.27--7.21 (m, 1H), 7.16 (d, *J* = 7.8 Hz, 1H), 7.15--7.10 (m, 2H), 7.08--7.01 (m, 2H), 5.14 (d, *J* = 9.5 Hz, 1H), 4.30--4.17 (m, 1H), 3.88 (dd, *J* = 10.8, 9.6 Hz, 1H), 3.20 (ddd, *J* = 17.4, 5.6, 1.3 Hz, 1H), 2.70 (ddd, *J* = 17.4, 4.1, 1.8 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.8, 176.6, 154.2, 139.1, 136.1, 134.6, 133.7, 133.6, 130.7, 128.8, 128.4, 128.0, 126.7, 123.9, 122.6, 122.3, 122.1, 117.7, 80.6, 46.3, 45.3, 36.2. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~19~ClNO~4~S^+^*m*/*z*: 452.0718; found: 452.0714. \[α\]~D~^20^ +13.7 (*c* = 1.42 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 32.39 min, *t*~minor~ = 13.77 min, ee = 98%.

### 2-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-2-(naphthalen-2-yl)chroman-4-yl)acetaldehyde (**7e**) {#sec3.4.5}

Yellow solid (24 mg, 51%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.70 (s, 1H), 7.77 (s, 1H), 7.72--7.63 (m, 2H), 7.61--7.58 (m, 2H), 7.53--7.51 (m, 1H), 7.41--7.23 (m, 5H), 7.13 (t, *J* = 7.3 Hz, 1H), 7.11--7.01 (m, 3H), 5.33 (d, *J* = 9.4 Hz, 1H), 4.42--4.24 (m, 1H), 3.98 (dd, *J* = 10.7, 9.6 Hz, 1H), 3.19 (ddd, *J* = 17.2, 5.6, 1.2 Hz, 1H), 2.73 (ddd, *J* = 17.3, 4.1, 1.9 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.9, 176.8, 154.4, 138.9, 134.7, 133.2, 133.1, 133.0, 132.7, 130.7, 128.7, 128.4, 128.0, 127.3, 126.8, 126.4, 126.4, 123.6, 123.4, 122.5, 122.1, 122.0, 117.7, 81.5, 46.4, 45.5, 36.0. ESI-HRMS: \[M + H\]^+^ calcd. For C~28~H~22~NO~4~S^+^*m*/*z*: 468.1264; found: 468.1267. \[α\]~D~^20^ +12.9 (*c* = 0.83 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 23.12 min, *t*~minor~ = 12.04 min, ee = 99%.

### 2-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-6-fluoro-2-phenylchroman-4-yl)acetaldehyde (**7f**) {#sec3.4.6}

Pale yellow solid (33 mg, 75%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.68 (s, 1H), 7.73 (d, *J* = 7.5 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.34 (d, *J* = 7.3 Hz, 2H), 7.17--7.07 (m, 3H), 7.04 (t, *J* = 7.4 Hz, 1H), 7.01--6.98 (m, 2H), 6.94 (td, *J* = 8.3, 2.6 Hz, 1H), 5.10 (d, *J* = 9.4 Hz, 1H), 4.28--4.19 (m, 1H), 3.90 (dd, *J* = 10.6, 9.6 Hz, 1H), 3.14 (ddd, *J* = 17.7, 5.6, 1.0 Hz, 1H), 2.73 (ddd, *J* = 17.8, 4.1, 1.4 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 200.3, 176.6, 158.6, 156.7, 150.5, 139.1, 137.3, 133.5, 133.3, 130.7, 128.9, 128.6, 126.5, 124.0, 122.3, 118.9, 118.8, 115.4, 115.2, 113.0, 112.8, 81.5, 46.2, 45.5, 36.0. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~19~FNO~4~S^+^*m*/*z*: 436.1013; found: 436.1009. \[α\]~D~^20^ +48.1 (*c* = 1.17 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 225 nm, *t*~major~ = 16.32 min, *t*~minor~ = 12.03 min, ee = 99%.

### 2-((2*R*,3*S*,4*R*)-3-(2,2-Dioxidobenzo\[*e*\]\[1,2,3\]oxathiazin-4-yl)-2-phenylchroman-4-yl)acetaldehyde (**7g**) {#sec3.4.7}

Pale yellow solid (36 mg, 84%); ^1^H NMR (500 MHz, CDCl~3~) δ 9.70 (s, 1H), 7.54--7.49 (m, 1H), 7.42 (d, *J* = 7.5 Hz, 1H), 7.34 (d, *J* = 7.4 Hz, 2H), 7.30 (d, *J* = 7.9 Hz, 1H), 7.23 (t, *J* = 7.7 Hz, 1H), 7.17--7.10 (m, 3H), 7.10--7.00 (m, 4H), 5.10 (d, *J* = 9.2 Hz, 1H), 4.29--4.21 (m, 1H), 4.14--4.05 (m, 1H), 3.20 (dd, *J* = 17.4, 5.5 Hz, 1H), 2.68 (ddd, *J* = 17.5, 3.8, 1.6 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 201.0, 180.8, 154.4, 153.0, 137.2, 137.2, 128.8, 128.6, 128.4, 128.3, 126.7, 126.6, 125.6, 122.7, 121.9, 118.7, 117.6, 117.2, 81.9, 49.1, 45.2, 36.4. ESI-HRMS: \[M + H\]^+^ calcd. For C~24~H~20~NO~5~S^+^*m*/*z*: 434.1057; found: 434.1059. \[α\]~D~^20^ +7.80 (*c* = 2.50 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH/CH~2~Cl~2~ = 80:17:3, 1 mL/min), λ = 260 nm, *t*~major~ = 11.05 min, *t*~minor~ = 8.49 min, ee = 97%.

Synthesis of Compound **10** {#sec3.5}
----------------------------

### (*E*)-4-((2*R*,3*S*,4*R*)-3-(1,1-Dioxidobenzo\[*d*\]isothiazol-3-yl)-2-phenylchroman-4-yl)-1-phenylbut-2-en-1-one (**9**) {#sec3.5.1}

The reaction was conducted with **2a** (0.50 mmol, 1.0 equiv) and **3a** (32 mg, 0.1 mmol) in CHCl~3~ (3.0 mL) at 25 °C, and then **1a** (0.60 mmol, 1.2 equiv) was added. After the reaction was completed, Ph~3~P=CHCOPh **8** (185 mg, 1.0 equiv) was added in situ, and the reaction was stirred at 25 °C for another 2 h. The product was purified by column chromatography on silica gel to provide product **9** as a yellow solid (175 mg, 67%). ^1^H NMR (500 MHz, CDCl~3~) δ 7.70 (d, *J* = 7.6 Hz, 1H), 7.59 (d, *J* = 7.3 Hz, 2H), 7.50 (t, *J* = 7.4 Hz, 1H), 7.45--7.41 (m, 2H), 7.36--7.32 (m, 4H), 7.28--7.23 (m, 1H), 7.14 (t, *J* = 7.6 Hz, 1H), 7.11--7.07 (m, 3H), 7.05 (d, *J* = 8.1 Hz, 1H), 6.99 (t, *J* = 7.4 Hz, 1H), 6.93 (d, *J* = 7.7 Hz, 1H), 6.83 (ddd, *J* = 15.1, 8.7, 6.3 Hz, 1H), 6.59 (d, *J* = 15.3 Hz, 1H), 5.16 (d, *J* = 9.4 Hz, 1H), 4.28--4.20 (m, 1H), 3.53 (dd, *J* = 10.9, 9.6 Hz, 1H), 3.09--2.94 (m, 1H), 2.83--2.69 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 189.1, 176.6, 154.7, 143.9, 139.1, 137.5, 137.0, 133.1, 133.0, 132.9, 130.7, 128.9, 128.7, 128.5, 128.5, 128.4, 128.3, 127.1, 126.5, 123.7, 122.4, 122.2, 122.0, 117.7, 81.0, 46.6, 39.2, 35.2.

### 2-((4*bR*,6*R*,12*bR*,12*cR*,13*R*)-12*b*-Methoxy-8,8-dioxido-13-phenyl-4*b*,5,12*b*,12*c*-tetrahydro-6*H*,13*H*-benzo\[4,5\]isothiazolo\[2,3-*a*\]chromeno\[3,4-*c*\]pyridin-6-yl)-1-phenylethan-1-one (**10**) {#sec3.5.2}

Compound **9** was dissolved into THF/MeOH = 4:1 (v/v, 5 mL), and Cs~2~CO~3~ (0.5 equiv) was added at 5 °C. After 1 h, the reaction turned into brown suspension; the reaction was extracted with water and ethyl acetate three times, collected the organic phase, dried with Na~2~SO~4~, and reduced the solvent by evaporation. The residue was purified by column chromatography on silica gel to provide product **10** as a white solid (110 mg, 60%). ^1^H NMR (500 MHz, CDCl~3~) δ 8.09 (d, *J* = 7.6 Hz, 2H), 7.64--7.54 (m, 2H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.25--7.16 (m, 3H), 7.11--7.06 (m, 3H), 7.02 (d, *J* = 7.5 Hz, 2H), 6.96 (t, *J* = 7.4 Hz, 1H), 6.87 (t, *J* = 7.6 Hz, 1H), 6.66 (d, *J* = 7.9 Hz, 1H), 6.53 (d, *J* = 7.9 Hz, 1H), 5.56 (d, *J* = 9.0 Hz, 1H), 4.55--4.45 (m, 2H), 3.72 (td, *J* = 11.7, 3.4 Hz, 1H), 3.50 (dd, *J* = 17.1, 5.2 Hz, 1H), 3.27 (s, 3H), 2.71 (dd, *J* = 11.2, 9.2 Hz, 1H), 2.49 (d, *J* = 12.6 Hz, 1H), 2.31 (dd, *J* = 24.5, 12.2 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~) δ 196.2, 153.6, 140.2, 136.7, 136.2, 135.8, 133.4, 130.5, 129.4, 128.7, 128.5, 128.4, 128.4, 128.2, 127.6, 127.5, 125.0, 124.9, 121.3, 120.7, 117.2, 93.4, 79.4, 50.8, 49.5, 48.6, 40.2, 34.0, 32.6. ESI-HRMS: \[M + H\]^+^ calcd. For C~33~H~30~NO~5~S^+^*m*/*z*: 552.1839; found: 552.1833. \[α\]~D~^20^ −16.3 (*c* = 0.67 in CHCl~3~). The enantiomeric excess was determined by HPLC analysis using a Daicel Chiralpak IB column (*n*-hexane/*i*-PrOH = 80:20, 1 mL/min), λ = 210 nm, *t*~major~ = 11.51 min, *t*~minor~ = 10.66 min, ee = 91%.
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